Citigroup
APRE icon

Citigroup’s Aprea Therapeutics APRE Stock Holding History

Citigroup’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$7 – 6049
2025
Q3 		$7 Buy
+5
New +$8 ﹤0.01% 5958
2025
Q1 		– Sell
-24
Closed -$79 – 5556
2024
Q4 		$79 Buy
+24
New +$80 ﹤0.01% 5698
2022
Q2 		– Sell
-25
Closed -$1K – 6211
2022
Q1 		$1K Buy
+25
New +$1.02K ﹤0.01% 6142
2021
Q4 		– Sell
-55
Closed -$6K – 5804
2021
Q3 		$6K Sell
55
-9
-14% -$818 ﹤0.01% 5564
2021
Q2 		$6K Sell
64
-38
-37% -$3.51K ﹤0.01% 5789
2021
Q1 		$10K Sell
102
-45
-31% -$5.25K ﹤0.01% 5620
2020
Q4 		$14K Buy
147
+108
+277% +$51.4K ﹤0.01% 6818
2020
Q3 		$19K Sell
39
-94
-71% -$52.6K ﹤0.01% 6221
2020
Q2 		$103K Buy
133
+37
+39% +$24.3K ﹤0.01% 5548
2020
Q1 		$67K Buy
96
+31
+48% +$22.7K ﹤0.01% 5699
2019
Q4 		$59K Buy
+65
New +$35.8K ﹤0.01% 6170

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's APRE Position: Q4 2025 in Review

Citigroup sold out of Aprea Therapeutics (APRE) in Q4 2025, closing a stake of 5 shares — an estimated $7 sold.

Citigroup first reported a position in APRE in Q4 2019 and held it in 11 quarters. The position peaked at $103K in Q2 2020. 22 funds tracked by Wall St. Rank hold APRE as of Q4 2025.

  • Citigroup reported no remaining Aprea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 5 Aprea Therapeutics shares in Q4 2025, an estimated $7.
  • Citigroup first reported a position in Aprea Therapeutics in Q4 2019 and held it in 11 quarters.
  • Citigroup's Aprea Therapeutics position peaked at $103K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.